Menu
Recruiting NCT06859411

Prognosis of Posterior Lamellar Keratoplasty

Observational Fuchs' Endothelial Corneal Dystrophy Pseudophakic Bullous Keratopathy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: visual acuity comparaison.
Who it may be relevant to
Registry conditions: Fuchs' Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Prognosis of Posterior Lamellar Keratoplasty: an Observational Cohort Study

Overview

Over the past decade, the management of Fuchs' endothelial corneal dystrophy (FECD) and pseudophakic bullous keratopathy (PBK) has been revolutionized by the development of posterior lamellar keratoplasty techniques: DSAEK and DMEK. DSAEK (Descemet Stripping Automated Endothelial Keratoplasty) involves replacing the patient's endothelium and pathological descemetum with a descemetic endothelial graft combined with a thin stromal lamella. The endothelial density of the grafts is generally greater than 2,400 cells/mm². Depending on the grafting center and tissue bank, grafts may be either pre-cut in the tissue bank or cut on the operating table by the surgeon himself. The donor graft is placed on an artificial anterior chamber, and automated microkeratome cutting produces grafts with an average thickness of 100 to 200µm, sometimes less than 100um (known as UT-DSAEK or ultra-thin DSAEK). DMEK (Descemet Membrane Endothelial Keratoplasty) is a strictly endothelium and Descemet's membrane graft, as close as possible to the original anatomy of the cornea. The graft is dissected manually either in a tissue bank (pre-cut grafts) or on the operating table by the surgeon. The thickness of the graft is between 15 and 18 microns. The primary objective of this observational cohort is to compare the evolution of visual acuity after DMEK, DSAEK or UT-DSAEK transplantation. Secondary objectives are to compare the evolution of endothelial cell density, corneal thickness and early and late post-operative complications, and to identify factors predictive of these different endpoints.

Interventions

  • Procedure visual acuity comparaison
    Data collection

Primary outcome measures

  • BSCVA [Time frame: at 1 year after surgery, but also at day 8, day 15, 1 month, 3 months, 6 months and every year up to 10 years after surgery]
Secondary outcome measures (3)
  • ECD [Time frame: at 1 month, 3 months, 6 months and every year up to 10 years after surgery]
  • CCT [Time frame: at 1 month, 3 months, 6 months and every year up to 10 years after surgery]
  • post-operative complication [Time frame: up to 10 years after surgery]

Eligibility criteria

Inclusion criteria

  • patients who received a posterior lamellar keratoplasty in Metz-Thionville Regional Hospital between 2012 and 2030

Exclusion criteria

  • patients refusing to take part in the study

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Cohort

Study locations

France · 1 center
  • CHR Metz-Thionville Hopital de Mercy — Metz

Publications

  • Delean S, Goetz C, Zevering Y, Perone JM. Central Corneal Thickness 6 Postoperative Months After Pseudophakic-Descemet Membrane Endothelial Keratoplasty, Triple-Descemet Membrane Endothelial Keratoplasty, and Cataract Surgery Alone: A Retrospective Cohort Study and Literature Review. Cornea. 2026 Mar 11. doi: 10.1097/ICO.0000000000004144. Online ahead of print. PMID 41921039

Identifiers

NCT: NCT06859411 · 2024-11Obs-CHRMT

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗